Work

Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib (GIDEON): Sorafenib dosing and safety in U.S. patients.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.4_suppl.302

Authors: Anthony B. El-Khoueiry, Bilal Piperdi, Alec Goldenberg, Allen Lee Cohn, Jeff H. Geschwind, Jorge A. Marrero, Arun Sanyal, Alan Paul Venook

Institutions: Montefiore Medical Center, Johns Hopkins University, University of California, San Francisco, Virginia Commonwealth University, University of Michigan, Johns Hopkins Medicine, NYU Langone Health, USC Norris Comprehensive Cancer Center, New York University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2252648041

Cites:

Cited by: 1

Related to: 10